Recent advances in preoperative hyperthermochemoradiotherapy for patients with esophageal cancer

Hiroshi Saeki, Hidetoshi Kawaguchi, Kaoru Kitamura, Shinji Ohno, Keizo Sugimachi

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background and Objectives: Hyperthermochemoradiotherapy (HCR) has been performed on numerous patients with esophageal cancer. The purpose of this study is to demonstrate the recent advances in HCR. Methods: From 1965 to 1997, 294 patients given preoperative chemoradiotherapy (CR) or HCR were classified according to the anticancer agent that was administered (CR; group A given bleomycin (BLM); group B given cis-diamminedichloroplatinum (II) (CDDP), HCR; group C given BLM; and Group D given CDDP). The local response and the long-term results were investigated. Results: The cases in which CR or HCR was evaluated to be effective numbered 44 (48.4%) in group A, 22 (73.3%) in group B, 79 (63.7%) in group C, and 36 (73.5%) in group D. A significant difference was observed between groups A and B (P < 0.05). The highest incidence of markedly effective cases was observed in group D. The 5- year survival rates for the group A and B patients were 17.2% and 43.9%, respectively (P < 0.01), while the same rates for those of groups C and D were 25.6% and 57.8%, respectively (P < 0.05). Our results thus showed CDDP to have a greater effect than BLM, while HCR had a greater effect than CR. Conclusions: Preoperative HCR has improved thanks to recent advances in anticancer agents.

Original languageEnglish
Pages (from-to)224-229
Number of pages6
JournalJournal of Surgical Oncology
Volume69
Issue number4
DOIs
Publication statusPublished - Dec 1 1998

Fingerprint

Chemoradiotherapy
Esophageal Neoplasms
Bleomycin
Antineoplastic Agents
Cisplatin
Survival Rate
Incidence

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Recent advances in preoperative hyperthermochemoradiotherapy for patients with esophageal cancer. / Saeki, Hiroshi; Kawaguchi, Hidetoshi; Kitamura, Kaoru; Ohno, Shinji; Sugimachi, Keizo.

In: Journal of Surgical Oncology, Vol. 69, No. 4, 01.12.1998, p. 224-229.

Research output: Contribution to journalArticle

Saeki, Hiroshi ; Kawaguchi, Hidetoshi ; Kitamura, Kaoru ; Ohno, Shinji ; Sugimachi, Keizo. / Recent advances in preoperative hyperthermochemoradiotherapy for patients with esophageal cancer. In: Journal of Surgical Oncology. 1998 ; Vol. 69, No. 4. pp. 224-229.
@article{e85852768f67449cab382861e96ceb6f,
title = "Recent advances in preoperative hyperthermochemoradiotherapy for patients with esophageal cancer",
abstract = "Background and Objectives: Hyperthermochemoradiotherapy (HCR) has been performed on numerous patients with esophageal cancer. The purpose of this study is to demonstrate the recent advances in HCR. Methods: From 1965 to 1997, 294 patients given preoperative chemoradiotherapy (CR) or HCR were classified according to the anticancer agent that was administered (CR; group A given bleomycin (BLM); group B given cis-diamminedichloroplatinum (II) (CDDP), HCR; group C given BLM; and Group D given CDDP). The local response and the long-term results were investigated. Results: The cases in which CR or HCR was evaluated to be effective numbered 44 (48.4{\%}) in group A, 22 (73.3{\%}) in group B, 79 (63.7{\%}) in group C, and 36 (73.5{\%}) in group D. A significant difference was observed between groups A and B (P < 0.05). The highest incidence of markedly effective cases was observed in group D. The 5- year survival rates for the group A and B patients were 17.2{\%} and 43.9{\%}, respectively (P < 0.01), while the same rates for those of groups C and D were 25.6{\%} and 57.8{\%}, respectively (P < 0.05). Our results thus showed CDDP to have a greater effect than BLM, while HCR had a greater effect than CR. Conclusions: Preoperative HCR has improved thanks to recent advances in anticancer agents.",
author = "Hiroshi Saeki and Hidetoshi Kawaguchi and Kaoru Kitamura and Shinji Ohno and Keizo Sugimachi",
year = "1998",
month = "12",
day = "1",
doi = "10.1002/(SICI)1096-9098(199812)69:4<224::AID-JSO6>3.0.CO;2-I",
language = "English",
volume = "69",
pages = "224--229",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Recent advances in preoperative hyperthermochemoradiotherapy for patients with esophageal cancer

AU - Saeki, Hiroshi

AU - Kawaguchi, Hidetoshi

AU - Kitamura, Kaoru

AU - Ohno, Shinji

AU - Sugimachi, Keizo

PY - 1998/12/1

Y1 - 1998/12/1

N2 - Background and Objectives: Hyperthermochemoradiotherapy (HCR) has been performed on numerous patients with esophageal cancer. The purpose of this study is to demonstrate the recent advances in HCR. Methods: From 1965 to 1997, 294 patients given preoperative chemoradiotherapy (CR) or HCR were classified according to the anticancer agent that was administered (CR; group A given bleomycin (BLM); group B given cis-diamminedichloroplatinum (II) (CDDP), HCR; group C given BLM; and Group D given CDDP). The local response and the long-term results were investigated. Results: The cases in which CR or HCR was evaluated to be effective numbered 44 (48.4%) in group A, 22 (73.3%) in group B, 79 (63.7%) in group C, and 36 (73.5%) in group D. A significant difference was observed between groups A and B (P < 0.05). The highest incidence of markedly effective cases was observed in group D. The 5- year survival rates for the group A and B patients were 17.2% and 43.9%, respectively (P < 0.01), while the same rates for those of groups C and D were 25.6% and 57.8%, respectively (P < 0.05). Our results thus showed CDDP to have a greater effect than BLM, while HCR had a greater effect than CR. Conclusions: Preoperative HCR has improved thanks to recent advances in anticancer agents.

AB - Background and Objectives: Hyperthermochemoradiotherapy (HCR) has been performed on numerous patients with esophageal cancer. The purpose of this study is to demonstrate the recent advances in HCR. Methods: From 1965 to 1997, 294 patients given preoperative chemoradiotherapy (CR) or HCR were classified according to the anticancer agent that was administered (CR; group A given bleomycin (BLM); group B given cis-diamminedichloroplatinum (II) (CDDP), HCR; group C given BLM; and Group D given CDDP). The local response and the long-term results were investigated. Results: The cases in which CR or HCR was evaluated to be effective numbered 44 (48.4%) in group A, 22 (73.3%) in group B, 79 (63.7%) in group C, and 36 (73.5%) in group D. A significant difference was observed between groups A and B (P < 0.05). The highest incidence of markedly effective cases was observed in group D. The 5- year survival rates for the group A and B patients were 17.2% and 43.9%, respectively (P < 0.01), while the same rates for those of groups C and D were 25.6% and 57.8%, respectively (P < 0.05). Our results thus showed CDDP to have a greater effect than BLM, while HCR had a greater effect than CR. Conclusions: Preoperative HCR has improved thanks to recent advances in anticancer agents.

UR - http://www.scopus.com/inward/record.url?scp=0032438560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032438560&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-9098(199812)69:4<224::AID-JSO6>3.0.CO;2-I

DO - 10.1002/(SICI)1096-9098(199812)69:4<224::AID-JSO6>3.0.CO;2-I

M3 - Article

C2 - 9881939

AN - SCOPUS:0032438560

VL - 69

SP - 224

EP - 229

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 4

ER -